Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
High ribavirin dose · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | PegIFN-alpha 2a + RBV (commenced according to kidney function) adjusted to plasma levels. Treatment with erythropoetin 3x3,000IU/week up to 3x10,000IU/week in case of hemolytic anemia |
| B | ACTIVE_COMPARATOR | PegIFN-alpha 2a + RBV (weight based; 1,000 or 1,200 mg/day) |
| Name | Type | Description |
|---|---|---|
| High ribavirin dose | DRUG | Ribavirin dose started according to kidney function (usually 1,800mg) and adapted according to plasma level during follow-up |
| Standard ribavirin dose | DRUG | Ribavirin dose started at 1,000mg (body weight \<65kg) or 1,200mg (body weight equal or \>65kg) |
Inclusion Criteria: * Male and female patients aged 18-65 years * Elevated liver enzymes levels * Compensated liver disease * Available liver histology confirming METAVIR F2 fibrosis * Written consent to participation Exclusion Criteria * Age \<18, \>65 * Prior ribavirin treatment * Intolerance t...
High ribavirin dose is used for the treatment of chronic hepatitis C. It is an investigational small molecule being studied in Phase 2 clinical trials for this infectious disease. The drug is being developed by Roche Holding AG (RHHBY).
High ribavirin dose is a small molecule antiviral. While the exact mechanism is not specified, ribavirin is known to interfere with viral RNA replication. It is being studied in combination with other antiviral agents for chronic hepatitis C.
High ribavirin dose is being developed by Roche Holding AG, which trades under the ticker RHHBY. Roche is conducting clinical trials to evaluate the drug's safety and efficacy in patients with chronic hepatitis C.
High ribavirin dose is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Two Phase 2 trials have been completed, with a total enrollment of 80 participants.
High ribavirin dose has been studied in two completed Phase 2 trials: NCT00944684, which evaluated high dose ribavirin in chronic hepatitis C, and NCT01482390, which studied mericitabine in combination with telaprevir and peginterferon alfa-2a/ribavirin. Both trials are completed.
High ribavirin dose refers to a higher dose of ribavirin, an antiviral medication. It is not a distinct drug but a dosing strategy. The trials listed include studies of ribavirin at higher doses, such as NCT00944684, which specifically investigated high dose ribavirin.